Martha Galvan, MD
Internal Medicine · Los Angeles, CANPI 1205274040
Payments from drug & device makers
Across 148 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$941
- Sanofi$878
- Regeneron Healthcare Solutions, Inc.$673
- Amgen$386
- Alk-abello, Inc$365
- GSK$346
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,123100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $941 |
| Sanofi | 17 | $878 |
| Regeneron Healthcare Solutions, Inc. | 25 | $673 |
| Amgen(2 entities) | 8 | $386 |
| Alk-abello, Inc | 15 | $365 |
| GSK | 13 | $346 |
| CSL Behring | 13 | $285 |
| Genentech USA, Inc. | 3 | $285 |
| Grifols USA, LLC | 7 | $168 |
| Novartis | 6 | $158 |
| Optinose US, Inc. | 6 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Octapharma USA, Inc. | 2 | $68 |
| Ionis Pharmaceuticals, Inc. | 2 | $67 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $50 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $41 |
| Pfizer | 2 | $40 |
| Boehringer Ingelheim | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,123 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $649 |
| Azelastine Hcl | 18 | $485 |
| Levothyroxine Sodium | 11 | $136 |
| Montelukast Sodium | 13 | $124 |
| Olmesartan Medoxomil | 11 | $116 |
| Lisinopril | 11 | $100 |
| Nortriptyline Hcl | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.